References
- Cheng K, Wu T-J, Wu KK, Sturino C, Metters K, Gottesdiener K, Wright SD, Wang Z, O’Neill G, Lai E, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proceedings of the National Academy of Sciences of the USA 2006; 103: 6682–6687
- Dean B, Chang S, Elipe M, Xia Y-Q, Braun M, Soli E, Zhao Y, Franklin R, Karanam B. Drug Metabolism and Disposition 2007; 35: 289–292
- Eklund B, Kaijser L, Nowak J, Wennmalm A. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins 1979; 17: 821–830
- Gentile S, Rubba P, Persico M, Bronzino P, Marmo R, Faccenda F. Improvement of the nicotinic acid test in the diagnosis of Gilbert's syndrome by pretreatment with indomethacin. Hepatogastroenterology 1985; 32: 267–269
- Iwaki M, Bischer A, Nguyen AC, McDonagh AF, Benet LZ. Stereoselective disposition of naproxen glucuronide in the rat. Drug Metabolism and Disposition 1995; 23: 1099–1103
- Knopp RH. Drug treatment of lipid disorders. New England Journal of Medicine 1999; 341: 498–511
- Kreiter PA, Colletti AE, Doss GA, Miller RR. Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Drug Metabolism and Disposition 1994; 22: 625–630
- Morrow JD, Awad JA, Oates JA, Roberts LJ, II. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. Journal of Investigative Dermatology 1992; 98: 812–815
- Nicoll-Griffith DA, Seto C, Aubin Y, Lévesque J-F, Chauret N, Day S, Silva JM, Trimble LA, Truchon JF, Berthelette C, Lachance N, Wang Z, Sturino C, Braun M, Zamboni R, Young RN. In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites. Bioorganic and Medicinal Chemistry Letters 2007; 17(2)301–304
- Rubenfire M. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the impact of medical subspeciality on patient compliance to treatment (IMPACT) study. American Journal of Cardiology 2004; 94: 306–311
- Shepherd J, Packard DJ, Patsch JR, Gotto AM, Jr, Taunton OD. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoptotein A metabolism. Journal of Clinical Investigation 1979; 63: 858–867
- Sturino CF, O’Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, Aubin Y, Kevin PKP, Chavret N, Day SH, Lévesque J-F, Seto C, Silva JH, Trinble LA, Carriere M-C, Denis D, Greig G, Kargman S, Lamontagne S, Mathieu M-C, Sawyer N, Slipetz D, Abraham WM, Jones T, McAuliffe M, Piechuta H, Nicholl-Griffin DA, Wang Z, Zamboni R, Young RN, Metters KM. Journal of Medicinal Chemistry 2007; 50(4)794–806, Discovery of a potent and selective Prostaglandin D2 receptor antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta [b]indol-3-yl]-acetic acid (MK-0524).
- Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. On behalf of the Nautilus Study Group, 2006. Evaluation of safety and tolerability of prolonged-release nicotonic acid in a usual care setting. Current Medical Research and Opinion 2006; 22: 417–425
- Zhao X-Q, Morse JS, Dowdy AA, Heise N, DeAngelis D, Frohlich J, Chait A, Albers JJ, Brown BG. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). American Journal of Cardiology 2004; 93: 307–312